Abstract
None of the FDA-approved Alzheimer’s disease (AD) treatments address the main hallmarks of the disease. With the recent clinical trial shortcomings of AD immunotherapy as well as γ- and β-secretase inhibitors among others, we and colleagues agree that a multifactorial approach is needed to address the polygenicity of AD. We used an epigenetic strategy where a single drug would simultaneously affect the expression of well-defined AD-related targets.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
